In detail, among GPP patients, 4 out of 7 patients (57.1%) underwent therapy with IL- 17-, 2 (28.6%), TNFα-, and 1 (14.3%) p40IL12/23- inhibitors. The gene discussed is TNF; the disease is psoriasis 14, pustular.